[English]  [Pусский]  [中文]  
ctt-journal > Zander et al. (Abstract)

Zander et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract79

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

Stem cell transplantation for malignant lymphoma – a review

Axel R. Zander, Tatjana Zabelina, Ulrike Bacher, Nicolaus Kröger

Interdisciplinary clinic for stem cell transplantation, University Hospital Hamburg-Eppendorf, Hamuburg, Germany

Correspondence: Prof. Dr. Axel R. Zander, Interdisciplinary Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamuburg, E-mail: arzzander@spam is badaol.de


High-dose therapy allows for dose-related response and a higher cure rate in sensitive malignancies. Autologous stem cell transplantation has been explored in malignant lymphomas for the last thirty years. Allogeneic stem cell transplantation carries the risk of graft-versus-host disease, but has a potential benefit: the graft versus leukemia/lymphoma effect with an increased cure rate. The results of conventional therapy in non-Hodgkin's lymphoma have been improved through the addition of Rituximab. Autologous transplantation is used as salvage treatment in most entities, in mantle cell lymphoma, and peripheral T-cell lymphoma as primary treatment. Allogeneic stem cell transplantation is used as salvage treatment in high risk CLL as well as in follicular lymphoma and mantle cell lymphoma. The role of allogeneic transplant in peripheral T-cell lymphoma is still open. There seems to be an indication for non-responders, but it may be indicated as primary treatment, too.

Hodgkin's lymphoma will be treated with autologous transplantation in a salvage situation. Allogeneic transplant is reserved for the treatment of relapse following an autologous transplant.

Keywords: NHL, Hodgkin's disease, allogeneic stem cell transplantation